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Abstract. Dihydroartemisinin–piperaquine (DP) is recommended for the treatment of uncomplicated malaria, used
in efforts to contain artemisinin resistance, and increasingly considered for mass drug administration. Because of the
narrow therapeutic dose range and available tablet strengths, the manufacturers and World Health Organization
recommended regimens involve breaking tablets into halves to accurately dose children according to body weight.
Use of tablet fractions in programmatic settings under tropical conditions requires a highly stable product; however,
the stability of DP tablet fractions is unknown. We aged full and half DP (Eurartesim®) tablets in a stability chamber at
30°C and 70% humidity level. The active pharmaceutical ingredients dihydroartemisinin and piperaquine remained at
≥ 95% over the 3 months’ period of ageing in light and darkness. These findings are reassuring for DP, but highlight
the need to assess drug stability under real-life settings during the drug development process, particularly for key
drugs of global disease control programs.
The antimalarial artemisinin-based combination therapy
dihydroartemisinin–piperaquine (DP) is highly efficacious
against uncomplicated malaria. Because of its long half-life
and associated chemoprophylactic effect, DP is considered
the most promising antimalarial for mass drug administration
(MDA) for transmission reduction efforts in Africa.1 Further-
more, it is extensively studied for intermittent preventive
treatment in children2,3 and pregnant women.4,5 The global
discussion around use of drugs to reduce transmission has
largely focused on DP’s pharmacokinetic and pharmaco-
dynamic properties, and those of suitable gametocytocidal
drugs, whereas more practical threats to successful imple-
mentation have received much less attention.
Eurartesim (Sigma-Tau Industrie Farmaceutiche Riunite
s.p.a., Rome, Italy), the only available fixed-dose combination
of DP that has obtained marketing authorization from a
stringent regulatory authority (i.e., the European Medicines
Agency, [EMA]), is available as pediatric tablets containing
20 mg dihydroartemisinin and 160 mg piperaquine, and adult
tablets containing 40 mg dihydroartemisinin and 320 mg
piperaquine.6 Due to the narrow therapeutic dose range and
limited number of tablet strengths, the manufacturer6 and
the World Health Organization (WHO)7 recommend breaking
tablets into halves to accurately dosing children according to
their body weight. There is no WHO guidance on age-based
dose regimens, where the use of half tablets may help limit
the substantial increase in dose intake variation.8
The major concern with tablet fractions, apart from inac-
curate dosing resulting from imprecise breaking of tablets,
is the intrinsic stability of broken tablets of DP under con-
ditions of high temperature and humidity found in malaria-
endemic countries. Drug decomposition and formation of
degradation products are typically accelerated in the pres-
ence of oxygen, moisture, heat, and strong light. As a con-
sequence, remaining tablet halves may contain lower dose
and, in the worst case, even toxic byproducts, potentially
resulting in lack of clinical response, adverse events, and
spread of antimalarial resistance. No data are available from
the manufacturer, EMA registration, or scientific literature
on the stability of DP tablet fractions once removed from
the blister pack. In this study, we determined the stability
of half tablets of DP at 37°C and 70% humidity as found in
malaria-endemic countries.9 The results address the gap in
knowledge on the stability of tablet halves of DP and this
crucial information will help the successful implementation
of MDA programs using DP.
Eurartesim (40/320 mg) tablets (N = 360; Lot 141450;
Exp 11/2016) were purchased from Manson’s Chemists Ltd
(London E78BA, United Kingdom). Other chemicals were of
high-performance liquid chromatography (HPLC) or analyti-
cal grade from various commercial sources.
The short-term stability of DP tablets halves was investi-
gated within their expiry date (January to April 2016) in a
“natural ageing” study over 3 months’ light on (320–400 nm)
and light off in climatic zone IV9 (30°C and 70% relative
humidity) using a pharmaceutical stability chambers (PSC022,
Weiss Gallenkamp, United Kingdom). Two hundred and
forty tablets were manually split in half using as fragmenta-
tion of tablets was rather high when using a pill cutter. The
halves were then put back in their blister. Supplemental
Figures 1–7 show the photos of tablets being broken manu-
ally and placed in the blister pack for ageing. Two hundred
and forty halves were kept in light and 240 halves in dark-
ness in the stability chamber. At defined time points, that
is, 0 hours (= nonaged), 24 hours, 3 days, 1 calendar
month, and 3 calendar months, 48 tablet halves from each
light exposure group were removed (Table 1), and stored
in their blister packs at 4°C until analysis (within 1 week of
removal from the chamber). One hundred and twenty full
tablets were used as controls (Table 1).
Quantitative analysis of dihydroartemisinin and piperaquine
was performed using a previously published HPLC with photo
diode array detection method.10 Each full tablet or half tablet
sample was dissolved in methanol first to obtain a 5 mg/mL
solution of dihydroartemisinin. The sample was sonicated
(10 minutes), 120 μL removed, and centrifuged. The superna-
tant (10 μL) was injected into the HPLC column and the amount
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of dihydroartemisinin present in the tablet was determined. To
the rest of the solution 2 M HCl in methanol was added to
obtain a 32 mg/mL stock solution of piperaquine, which was
further diluted to get a 0.6 mg/mL dilute which was injected
(20 μL) onto the HPLC column. HPLC analysis was conducted
using a Dionex Ultimate 3000 system (Thermofisher, Hemel
Hempstead, UK) and for the analysis of piperaquine, sepa-
ration achieved using a Acclaim 120, C18, 5 μm Analytical
(4.6 × 150 mm, Fisher Scientific, Leicestershire, UK). The
mobile phase was a gradient of ammonium formate (10 mM,
pH 2.7) and acetonitrile (v/v; 15:85 to 85:15 over 7.0 minutes).
The separation of dihydroartemisinin was achieved using a
GENESIS AQ 4 μm column (150 × 4.6 mm, Grace Mate-
rials Technologies, Cranforth, UK). The mobile phase
was a gradient of ammonium formate (10 mM, pH 2.7) and
acetonitrile (v/v; 30:70 over 5.0 minutes). The photodiode
array detector (UV-PDA; DAD 3000) was set at 204 nm for
dihydroartemisinin and 360 nm for piperaquine.
We tested the stability of Eurartesim full tablets and tablet
halves when exposed to light or darkness at 30°C and 70%
relative humidity for up to 3 months. The weights of tablets
manually broken in half show the accuracy of this process
(Table 2) and both, dihydroartemisinin and piperaquine
amounts, remain fairly constant over 3 months in each group
(Table 3). This addresses a key gap in implementation
research, and reassures national malaria control programmes
considering using DP for MDA as this will ensure the reduc-
tion of cost and wastage of unused tablet fractions.
The International Conference on Harmonization and the
WHO state that to properly assess long-term stability of fin-
ished pharmaceutical products, testing on how the quality of
the product varies with time under the influence of tempera-
ture, humidity, and light should be conducted under storage
conditions experienced in the intended market. A recent
study found that full tablets of Coartem® (Novartis Pharma
AG, Basel, Switzerland) (artemether–lumefantrine) and ASAQ
Winthrop® (Sanofi-Aventis, Gentilly, France) (artesunate–
amodiaqiuine) were stable when “naturally aged” under tropi-
cal conditions. Acceptable levels of all active pharmaceutical
ingredients (90–110% as per international pharmacopeia tol-
erance limits) were measured over 3 years, despite drugs
having reached their expiry dates within 18–24 months
from the start of the study.11
Information on the stability of tablet fractions is crucial
especially when the number of available tablet strengths is
limited to accurately dose all patient groups. In the case of
DP, the manufacturer6 and the WHO7 recommend dosing
regimen that, with the only available fixed-dose combina-
tion that has obtained marketing authorization from a strin-
gent regulatory authority, can only be achieved by breaking
tablets into halve. Although for individual treatment, care-
givers can be advised to discard unused tablet fractions
immediately after having administered the dose to the
child to ensure no substandard tablets are administered
during subsequent dosing time points, adherence to this
strategy is not well known and seems even less feasible in
an MDA setting where large quantities of wastage would be
produced (with environmental and economic conse-
quences). More information on stability of tablet fractions is
therefore crucial for successful implementation of DP in
programmatic settings as the knowledge base for drugs
degraded as a result of storage in tropical climates is
sparse at best12–14 and nonexistent for half tablets.
Findings from our study are product specific and cannot
be extrapolated to other DP brands or formulations.
Information on stability of tablet fractions is crucial for
successful implementation in programmatic settings, espe-
cially for drugs involving dosing recommendations based
on tablet fractions in the absence of a child-friendly formu-
lation. We recommend this type of information be collected
much earlier in the drug development process and clearly
stated on the package insert.
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TABLE 2
Weight of tablets analyzed
Light Dark
Exposure Full tablets Half tablets Full tablets Half tablets
Nonaged 0.5318 (0.004) 0.2597 (0.016) 0.5332 (0.005) 0.2647 (0.011)
24 hours 0.5315 (0.006) 0.2652 (0.010) 0.5306 (0.006) 0.2673 (0.019)
3 days 0.5334 (0.006) 0.2684 (0.017) 0.5315 (0.003) 0.2677 (0.013)
1 month 0.5361 (0.006) 0.2691 (0.010) 0.5336 (0.005) 0.2678 (0.012)
3 months 0.5338 (0.004) 0.2678 (0.011) 0.5393 (0.006) 0.2671 (0.014)
Mean weight in grams (standard deviation) for the numbers of tablets and tablet halves specified in Table 1.
TABLE 1
Number of tablets analyzed
Light Dark
Exposure Full tablets Half tablets Full tablets Half tablets
Nonaged 12 24 (48 × ½) 12 24 (48 × ½)
24 hours 12 24 (48 × ½) 12 24 (48 × ½)
3 days 12 24 (48 × ½) 12 24 (48 × ½)
1 month 12 24 (48 × ½) 12 24 (48 × ½)
3 months 12 24 (48 × ½) 12 24 (48 × ½)
Total 60 120 (240 × ½) 60 120 (240 × ½)
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TABLE 3
Amounts of dihydroartemisinin (DHA) and piperaquine (PPQ) measured over time
Light Dark
Full tablets Half tablets Full tablets Half tablets
Exposure DHA PPQ DHA PPQ DHA PPQ DHA PPQ
Nonaged 4.98
(0.0039; 99.6)
0.60
(0.0009; 100.0)
4.96
(0.1249; 99.1)
0.58
(0.0172; 96.7)
4.96
(0.0648; 99.2)
0.60
(0.0193; 99.4)
4.98
(0.1133; 99.6)
0.60
(0.009; 99.8)
24 hours 4.99
(0.1614; 99.9)
0.59
(0.0126; 98.8)
4.96
(0.1056; 99.2)
0.59
(0.0179; 98.3)
4.96
(0.1506; 99.4)
0.59
(0.0160; 97.9)
4.97
(0.7207; 99.4)
0.6
(0.0932; 100.4)
3 days 4.94
(0.1132; 98.9)
0.56
(0.0258; 93.1)
4.93
(0.1736; 98.7)
0.56
(0.0312; 93.9)
4.96
(0.0808; 99.2)
0.59
(0.0148; 98.5)
4.96
(0.0989; 99.1)
0.58
(0.0250; 99.8)
1 month 4.92
(0.4742; 98.4)
0.56
(0.0311; 93.1)
4.93
(0.2359; 98.7)
0.57
(0.0341; 94.2)
4.94
(0.1184; 98.8)
0.58
(0.0196; 96.2)
4.93
(0.1404; 98.7)
0.57
(0.0283; 94.4)
3 months 4.90
(0.0822; 98.0)
0.57
(0.0216; 95.4)
4.92
(0.1203; 98.5)
0.57
(0.0272; 95.8)
4.91
(0.0402; 98.2)
0.58
(0.0032; 96.1)
4.90
(0.2216; 97.9)
0.58
(0.0294; 97.1)
Mean amount in mg/mL (SD; % active pharmaceutical ingredient) for the numbers of tablets and tablet halves specified in Table 1.
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